What is Armata Pharmaceuticals Earnings Yield (Joel Greenblatt) %?
Armata Pharmaceuticals's Enterprise Value for the quarter that ended in Dec. 2023 was $223.89 Mil.
Armata Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $-69.36 Mil. Armata Pharmaceuticals's Earnings Yield (Joel Greenblatt) for the quarter that ended in Dec. 2023 was -29.67%.
The historical rank and industry rank for Armata Pharmaceuticals's Earnings Yield (Joel Greenblatt) % or its related term are showing as below:
ARMP'
s Earnings Yield (Joel Greenblatt) % Range Over the Past 10 Years
Min: -8849.16 Med: -87.6 Max: 158400
Current: -31.75
During the past 13 years, the highest Earnings Yield (Joel Greenblatt) of Armata Pharmaceuticals was 158400.00%. The lowest was -8849.16%. And the median was -87.60%.
ARMP's Earnings Yield (Joel Greenblatt) % is ranked worse than 65.55% of 1408
companies
in the Biotechnology industry
Industry Median: -14.54
vs ARMP: -31.75
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
A better indicator of the attractiveness of an investment which takes growth into account is the Forward Rate of Return (Yacktman) %. Armata Pharmaceuticals's Forward Rate of Return (Yacktman) % for the quarter that ended in Dec. 2023 was 0.00%. The Forward Rate of Return uses the normalized Free Cash Flow of the past seven years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.
Armata Pharmaceuticals Earnings Yield (Joel Greenblatt) % Historical Data
The historical data trend for Armata Pharmaceuticals's Earnings Yield (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Armata Pharmaceuticals Earnings Yield (Joel Greenblatt) % Chart
Competitive Comparison of Armata Pharmaceuticals's Earnings Yield (Joel Greenblatt) %
For the Biotechnology subindustry, Armata Pharmaceuticals's Earnings Yield (Joel Greenblatt) %, along with its competitors' market caps and Earnings Yield (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Armata Pharmaceuticals's Earnings Yield (Joel Greenblatt) % Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Armata Pharmaceuticals's Earnings Yield (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where Armata Pharmaceuticals's Earnings Yield (Joel Greenblatt) % falls into.
Armata Pharmaceuticals Earnings Yield (Joel Greenblatt) % Calculation
In his book, The Little That Beat the Market, hedge fund manager Joel Greenblatt defines Earnings Yield as operating income divided by enterprise value.
Armata Pharmaceuticalss Earnings Yield (Joel Greenblatt) for the fiscal year that ended in Dec. 2023 is calculated as
Armata Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-69.36 Mil.
Armata Pharmaceuticals (AMEX:ARMP) Earnings Yield (Joel Greenblatt) % Explanation
Joel Greenblatt defines the earnings yield using the above equation because it more accurately reflects the company's profitability relative to its stock price. Items like interest payment and tax etc. are not directly related to the company's operational profitability.
Enterprise Value instead of market cap (share price) is used in the calculation because it is the real price stock and bond investors together pay for the company.
Be Aware
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
Armata Pharmaceuticals Earnings Yield (Joel Greenblatt) % Related Terms
Thank you for viewing the detailed overview of Armata Pharmaceuticals's Earnings Yield (Joel Greenblatt) % provided by GuruFocus.com. Please click on the following links to see related term pages.
Armata Pharmaceuticals (Armata Pharmaceuticals) Business Description
Armata Pharmaceuticals Inc is a developer of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. It is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. In addition, in collaboration with Merck the company is developing proprietary synthetic phage candidates to target an undisclosed infectious disease agent. Further, the company is committed to advancing phage with drug development expertise that spans bench to clinic including in-house phage specific GMP manufacturing.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ARMP has been successfully added to your 